Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members
about
Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast CancerNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewState of the art management of metastatic gastroesophageal cancerAdvances in targeted therapies and new promising targets in esophageal cancerPotential prognostic, diagnostic and therapeutic markers for human gastric cancerCoarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylationErbb2 is required for cardiac atrial electrical activity during developmentFrom molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancerExamining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based ModelPredictive Power Estimation Algorithm (PPEA)--a new algorithm to reduce overfitting for genomic biomarker discoveryOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative meA disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implicationsNanoparticles for Improving Cancer Diagnosis.Raman imaging at biological interfaces: applications in breast cancer diagnosisNF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance.Dynamic probabilistic threshold networks to infer signaling pathways from time-course perturbation data.Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.Detecting disease associated modules and prioritizing active genes based on high throughput data.Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging.The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interactionΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cellsHuman Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsExpression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancerRaman spectroscopy and imaging: applications in human breast cancer diagnosis.Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients.The role of radiotherapy-resistant stem cells in breast cancer recurrence.The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy.Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumabGamma tocotrienol targets tyrosine phosphatase SHP2 in mammospheres resulting in cell death through RAS/ERK pathway.Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer.Herbal tonic does not inhibit estrogen receptor negative mammary tumor development in a transgenic mouse model.Genetics of Bladder Malignant Tumors in Childhood
P2860
Q26738987-CA99D300-ABBD-4256-830B-95367CF0DBFAQ26764879-93E3F3FF-4974-40CF-BB25-E5588CE2B0FEQ26772969-C9D9337C-3F60-4786-92A8-1CE1733C204CQ26777733-ED8D4A22-177B-4736-8B1C-974AFF551BD7Q26779217-0341C6EE-B6D6-4814-80D0-4F1BA65B9D06Q26825957-CB69EB51-6E7D-4A4D-95D2-322B86DEFF69Q26866200-BE77484D-7C48-4FC3-900E-BF314DA933DBQ27323236-BBBF7F63-D058-43BA-A364-9661EC80F003Q27348830-528F9327-07D6-44BA-8191-4D41D752FA94Q28082921-ED26253A-DF30-4DCA-8E9A-A0D22DBDE3CBQ28390826-DE60558C-D1EB-4922-8B74-7DA4A3112328Q28477085-F9BA7C86-A82C-4BAB-9B23-89A6773A07AAQ30376023-78671056-E991-4BC4-AFD1-191944185478Q30430629-C88B87E6-63E4-43B7-A277-7B77F0B2F8A2Q30442412-0798F98C-5230-4F39-A0AF-588D39731748Q30453538-4204C4CC-1D9E-4B4A-A3EB-3F1520021885Q30486628-9DDDD00A-04C2-4F86-AF56-5320940A2C31Q30837758-21591FB2-3305-4923-B94D-08818D34DAD9Q33454999-1BC1A62C-0AA7-428F-8E1C-BCBCF05BEC05Q33523628-B5F5DA45-35DE-4AFC-9EB5-5375FD58A2B6Q33562598-76A26080-BEF8-464F-B0D0-FDB113AB73E5Q33609935-8AC41C72-8F71-4005-A9AC-8E97A8BEE0BFQ33719411-E48292E9-5681-47C7-8ABD-C94BC5CEEEE4Q33929273-15C0A4BF-14E1-457B-B753-1DA80D67473CQ33945648-5F763B11-F1A0-4E17-B1D4-72DE60743D46Q34223494-849F2DBF-CDA0-4963-8DEB-04E9352A77DCQ34253654-5E8486E0-2AEA-4B0F-BBDA-7AC68CFC89BDQ34324062-159943E6-B7BF-48C3-BDA2-B1B72311B656Q34390516-E3601B0D-7F8C-4387-9586-590E17FA22E5Q34575276-8FC45B9F-5495-4CD9-A2BB-9987886008DFQ34972167-F0B09B64-3F07-4C38-B8FB-2E23352EFCDDQ35094666-580E12DB-C0D2-4497-8FA9-5343D756E8B7Q35166541-333C0500-A9AC-4036-A21C-4D655FD35AC0Q35234716-33D3CAF9-F855-4393-9182-00C41DB97EC1Q35757946-6635CF33-51FB-47F9-8F05-6E8E01BD2981Q35835794-AA8FF860-DDB7-4ACE-B89A-B0CBEE0DFB02Q35846896-CDA7BCBE-6D17-4FB0-998A-83F9252917D6Q35851930-0D642D6E-8E5A-44DA-A8E9-53DBA2B2AA1FQ36456297-EF1A548E-313B-4D00-B63D-BA948EFA36EAQ36658484-101DDBC4-6168-4793-B3B6-B845994B39EF
P2860
Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@ast
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@en
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@en-gb
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@nl
type
label
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@ast
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@en
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@en-gb
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@nl
prefLabel
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@ast
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@en
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@en-gb
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@nl
P2860
P921
P3181
P356
P1476
Update on HER-2 as a target fo ...... ErbB2/HER-2 and family members
@en
P2093
M A Olayioye
P2860
P2888
P3181
P356
10.1186/BCR327
P407
P577
2001-10-04T00:00:00Z
P5875
P6179
1031969996